{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:20:21Z","timestamp":1789924821993,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005386","name":"Israeli Centers for Research Excellence","doi-asserted-by":"publisher","award":["41\/11"],"award-info":[{"award-number":["41\/11"]}],"id":[{"id":"10.13039\/501100005386","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nofar","award":["50653"],"award-info":[{"award-number":["50653"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12974-016-0648-x","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T11:32:37Z","timestamp":1467977557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)"],"prefix":"10.1186","volume":"13","author":[{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Charbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livnat","family":"Brill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oded","family":"Abramsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devorah","family":"Gur-Wahnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iddo Z.","family":"Ben-Dov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Lavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,8]]},"reference":[{"issue":"9","key":"648_CR1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"4","key":"648_CR2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473\u20137.","journal-title":"J Exp Med"},{"key":"648_CR3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fncel.2013.00150","volume":"7","author":"KS Sheinerman","year":"2013","unstructured":"Sheinerman KS, Umansky SR. Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci. 2013;7:150.","journal-title":"Front Cell Neurosci"},{"issue":"17","key":"648_CR4","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.4155\/fmc.14.116","volume":"6","author":"V Baumann","year":"2014","unstructured":"Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem. 2014;6(17):1967\u201384.","journal-title":"Future Med Chem"},{"issue":"100","key":"648_CR5","doi-asserted-by":"crossref","first-page":"ra81","DOI":"10.1126\/scisignal.2000610","volume":"2","author":"A Zernecke","year":"2009","unstructured":"Zernecke A et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100):ra81.","journal-title":"Sci Signal"},{"issue":"6","key":"648_CR6","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi H et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654\u20139.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"648_CR7","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1073\/pnas.1019055108","volume":"108","author":"JD Arroyo","year":"2011","unstructured":"Arroyo JD et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"648_CR8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","volume":"13","author":"KC Vickers","year":"2011","unstructured":"Vickers KC et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423\u201333.","journal-title":"Nat Cell Biol"},{"key":"648_CR9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12974-015-0418-1","volume":"12","author":"A Keller","year":"2015","unstructured":"Keller A et al. Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. J Neuroinflammation. 2015;12:196.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"648_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1\u201316.","journal-title":"J Neurol"},{"issue":"4","key":"648_CR11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"DJ Kimbrough","year":"2012","unstructured":"Kimbrough DJ et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1(4):180\u20137.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"648_CR12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","volume":"10","author":"MC Papadopoulos","year":"2014","unstructured":"Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10(9):493\u2013506.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"648_CR13","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","volume":"71","author":"SY Huh","year":"2014","unstructured":"Huh SY et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71(11):1372\u20138.","journal-title":"JAMA Neurol"},{"issue":"11","key":"648_CR14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443\u20138.","journal-title":"Arch Neurol"},{"issue":"10","key":"648_CR15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225\u201330.","journal-title":"Mult Scler"},{"issue":"Pt 11","key":"648_CR16","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(Pt 11):3072\u201380.","journal-title":"Brain"},{"issue":"10","key":"648_CR17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485\u20139.","journal-title":"Neurology"},{"issue":"11","key":"648_CR18","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1073\/pnas.1214046110","volume":"110","author":"Z Williams","year":"2013","unstructured":"Williams Z et al. Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc Natl Acad Sci U S A. 2013;110(11):4255\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"648_CR19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymeth.2012.07.020","volume":"58","author":"TA Farazi","year":"2012","unstructured":"Farazi TA et al. Bioinformatic analysis of barcoded cDNA libraries for small RNA profiling by next-generation sequencing. Methods. 2012;58(2):171\u201387.","journal-title":"Methods"},{"issue":"12","key":"648_CR20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"1","key":"648_CR21","doi-asserted-by":"crossref","first-page":"e0147249","DOI":"10.1371\/journal.pone.0147249","volume":"11","author":"IZ Ben-Dov","year":"2016","unstructured":"Ben-Dov IZ et al. Cell and microvesicle urine microRNA deep sequencing profiles from healthy individuals: observations with potential impact on biomarker studies. PLoS One. 2016;11(1):e0147249.","journal-title":"PLoS One"},{"issue":"9","key":"648_CR22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110\u20137.","journal-title":"JAMA Neurol"},{"issue":"9","key":"648_CR23","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2015.1421","volume":"72","author":"WO Tobin","year":"2015","unstructured":"Tobin WO, Pittock SJ. Rituximab therapy in neuromyelitis optica: moving toward a personalized medicine approach. JAMA Neurol. 2015;72(9):974\u20137.","journal-title":"JAMA Neurol"},{"issue":"3","key":"648_CR24","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/gb-2004-5-3-r13","volume":"5","author":"LF Sempere","year":"2004","unstructured":"Sempere LF et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004;5(3):R13.","journal-title":"Genome Biol"},{"issue":"9","key":"648_CR25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0960-9822(02)00809-6","volume":"12","author":"M Lagos-Quintana","year":"2002","unstructured":"Lagos-Quintana M et al. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735\u20139.","journal-title":"Curr Biol"},{"issue":"9","key":"648_CR26","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/gb-2004-5-9-r68","volume":"5","author":"EA Miska","year":"2004","unstructured":"Miska EA et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 2004;5(9):R68.","journal-title":"Genome Biol"},{"issue":"7","key":"648_CR27","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2007.04.040","volume":"129","author":"P Landgraf","year":"2007","unstructured":"Landgraf P et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401\u201314.","journal-title":"Cell"},{"key":"648_CR28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/1471-2164-15-474","volume":"15","author":"P Leidinger","year":"2014","unstructured":"Leidinger P et al. The human miRNA repertoire of different blood compounds. BMC Genomics. 2014;15:474.","journal-title":"BMC Genomics"},{"key":"648_CR29","doi-asserted-by":"crossref","unstructured":"Cubillos-Ruiz JR, et al. Reprogramming immune responses via microRNA modulation. Microrna Diagn Ther. 2013. 1(1).","DOI":"10.2478\/micrnat-2013-0001"},{"issue":"12","key":"648_CR30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrrheum.2012.142","volume":"8","author":"N Shen","year":"2012","unstructured":"Shen N et al. MicroRNAs\u2014novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol. 2012;8(12):701\u20139.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"648_CR31","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/1352458515578771","volume":"21","author":"R Gandhi","year":"2015","unstructured":"Gandhi R. miRNA in multiple sclerosis: search for novel biomarkers. Mult Scler. 2015;21(9):1095\u2013103.","journal-title":"Mult Scler"},{"issue":"Pt 12","key":"648_CR32","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1093\/brain\/awp300","volume":"132","author":"A Junker","year":"2009","unstructured":"Junker A et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009;132(Pt 12):3342\u201352.","journal-title":"Brain"},{"issue":"8","key":"648_CR33","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7150\/ijms.8647","volume":"11","author":"X Ma","year":"2014","unstructured":"Ma X et al. Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci. 2014;11(8):810\u20138.","journal-title":"Int J Med Sci"},{"issue":"3","key":"648_CR34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1352458513496343","volume":"20","author":"A Keller","year":"2014","unstructured":"Keller A et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler. 2014;20(3):295\u2013303.","journal-title":"Mult Scler"},{"issue":"9","key":"648_CR35","doi-asserted-by":"crossref","first-page":"e24604","DOI":"10.1371\/journal.pone.0024604","volume":"6","author":"A Waschbisch","year":"2011","unstructured":"Waschbisch A et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One. 2011;6(9):e24604.","journal-title":"PLoS One"},{"issue":"8","key":"648_CR36","doi-asserted-by":"crossref","first-page":"16087","DOI":"10.3390\/ijms140816087","volume":"14","author":"M Hecker","year":"2013","unstructured":"Hecker M et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Mol Sci. 2013;14(8):16087\u2013110.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"648_CR37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clim.2012.04.002","volume":"144","author":"C Sievers","year":"2012","unstructured":"Sievers C et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol. 2012;144(1):70\u20139.","journal-title":"Clin Immunol"},{"issue":"1","key":"648_CR38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/acn3.152","volume":"2","author":"J Ingwersen","year":"2015","unstructured":"Ingwersen J et al. Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. Ann Clin Transl Neurol. 2015;2(1):43\u201355.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"648_CR39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12060","volume":"253","author":"CZ Chen","year":"2013","unstructured":"Chen CZ et al. Regulation of immune responses and tolerance: the microRNA perspective. Immunol Rev. 2013;253(1):112\u201328.","journal-title":"Immunol Rev"},{"issue":"2","key":"648_CR40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2144\/000114133","volume":"56","author":"SR Head","year":"2014","unstructured":"Head SR et al. Library construction for next-generation sequencing: overviews and challenges. Biotechniques. 2014;56(2):61\u20134. 66, 68, passim.","journal-title":"Biotechniques"},{"key":"648_CR41","doi-asserted-by":"crossref","first-page":"342524","DOI":"10.1155\/2014\/342524","volume":"2014","author":"I Duroux-Richard","year":"2014","unstructured":"Duroux-Richard I et al. Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediators Inflamm. 2014;2014:342524.","journal-title":"Mediators Inflamm"},{"issue":"11","key":"648_CR42","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412\u201320.","journal-title":"Arch Neurol"},{"issue":"9","key":"648_CR43","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989\u201395.","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-016-0648-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T21:43:06Z","timestamp":1656798186000},"score":1,"resource":{"primary":{"URL":"http:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-016-0648-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,8]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1186\/s12974-016-0648-x","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,8]]},"article-number":"179"}}